CELC Profile
Celcuity Inc., based in Minneapolis, Minnesota, is a clinical-stage biotechnology firm specializing in the development of molecularly targeted therapies for cancer treatment. Founded in 2011, the company focuses on leveraging its innovative CELsignia diagnostic platform to personalize cancer care. This cutting-edge technology utilizes a patient's living tumor cells to pinpoint specific abnormal cellular processes driving their cancer, allowing for the identification of tailored targeted therapies.
Celcuity's lead drug candidate, Gedatolisib, is an advanced therapeutic designed to selectively target various class I isoforms of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound is primarily aimed at treating hormone receptor-positive, HER2-negative, and advanced or metastatic breast cancer. Gedatolisib's development underscores Celcuity's commitment to addressing complex cancer types with precision-targeted treatments.
In addition to Gedatolisib, Celcuity is advancing its CELsignia MP test, a laboratory-developed qualitative test that evaluates HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. This test is designed to enhance the understanding of tumor biology and improve the selection of appropriate therapies for patients with these cancers. Celcuity's strategic collaboration with Pfizer Inc. highlights the company's efforts to bring Gedatolisib to market, with Pfizer holding the development and commercialization rights.
Celcuity's innovative approach to cancer treatment, combining advanced diagnostics with targeted therapeutics, positions it at the forefront of precision medicine. By focusing on personalized treatment strategies and leveraging its proprietary technologies, the company aims to significantly impact the landscape of cancer care and improve outcomes for patients facing challenging and advanced cancer diagnoses.
|
